ALK and neoplasm: Most recently a phase II platform trial of once daily brigatinib (an inhibitor of ALK and multiple other tyrosine kinases) demonstrated hearing improvement (35% of ears) and radiographic response (10% of target tumours), with the greatest responses seen for meningiomas and non-vestibular schwannomas [54].